Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).

Participants needed: 75
Trial details
Phase: Phase 3Age: 2-17Biological sex: AllType: InterventionalSponsor: AMAG Pharmaceuticals, Inc.Updated: Apr 17, 2026Locations: 15
Eligibility criteria

Male or female 2 years to <18 years of age at time of consent [+4]

Known hypersensitivity reaction to any component of ferumoxytol or iron sucrose [+6]

Read more
Status: Recruiting

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

Participants needed: 129
Trial details
Phase: Phase 3Age: 2-17Biological sex: AllType: InterventionalSponsor: AMAG Pharmaceuticals, Inc.Updated: Apr 17, 2026Locations: 21
Eligibility criteria

Male or female 2 years to <18 years of age at time of consent [+7]

Known hypersensitivity reaction to any component of ferumoxytol and iron sucrose [+5]

Read more